Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
Key findingAnalysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or car
What the researchers found
Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Three randomized trials, 48-72 weeks duration. Weight changes compared between MASLD/MASH patients with and without type 2 diabetes.
How the study worked
In publication.
Who was studied
Adults with MASLD/MASH with and without type 2 diabetes
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
Diabetes, obesity & metabolism, 27(2), 710-718
Citation
Armstrong, Matthew J; Okanoue, Takeshi; Sundby Palle, Mads; Sejling, Anne-Sophie; Tawfik, Mohamed; Roden, Michael. (2025). Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.. Diabetes, obesity & metabolism, 27(2), 710-718. https://doi.org/10.1111/dom.16065